Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 22 | 2017 | 607 | 1.530 |
Why?
|
| Platinum | 11 | 2014 | 21 | 1.090 |
Why?
|
| Acridines | 13 | 2014 | 19 | 1.080 |
Why?
|
| Deoxycytidine | 3 | 2017 | 68 | 0.610 |
Why?
|
| Organoplatinum Compounds | 5 | 2014 | 47 | 0.430 |
Why?
|
| Thiourea | 5 | 2015 | 5 | 0.420 |
Why?
|
| Neoplasms | 4 | 2019 | 692 | 0.400 |
Why?
|
| Cell Line, Tumor | 18 | 2020 | 725 | 0.400 |
Why?
|
| Nucleosides | 2 | 2016 | 10 | 0.380 |
Why?
|
| Prodrugs | 2 | 2014 | 16 | 0.380 |
Why?
|
| DNA | 7 | 2014 | 228 | 0.370 |
Why?
|
| Drug Design | 8 | 2014 | 43 | 0.360 |
Why?
|
| Intercalating Agents | 5 | 2014 | 9 | 0.350 |
Why?
|
| Lipids | 2 | 2016 | 229 | 0.340 |
Why?
|
| Ovarian Neoplasms | 2 | 2007 | 94 | 0.330 |
Why?
|
| Drug Screening Assays, Antitumor | 12 | 2017 | 58 | 0.310 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2017 | 104 | 0.290 |
Why?
|
| Hyperthermia, Induced | 2 | 2007 | 246 | 0.290 |
Why?
|
| Nitrobenzenes | 1 | 2006 | 10 | 0.280 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 15 | 0.280 |
Why?
|
| HL-60 Cells | 5 | 2008 | 14 | 0.270 |
Why?
|
| Sulfonamides | 1 | 2006 | 67 | 0.270 |
Why?
|
| DNA Damage | 4 | 2017 | 98 | 0.270 |
Why?
|
| Cytarabine | 2 | 2017 | 55 | 0.260 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2005 | 49 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 461 | 0.240 |
Why?
|
| Phosphatidic Acids | 1 | 2003 | 1 | 0.230 |
Why?
|
| Apoptosis | 4 | 2017 | 354 | 0.230 |
Why?
|
| Coordination Complexes | 2 | 2015 | 9 | 0.210 |
Why?
|
| Gold | 2 | 2015 | 18 | 0.210 |
Why?
|
| Humans | 31 | 2020 | 32024 | 0.210 |
Why?
|
| Anisomycin | 1 | 2002 | 3 | 0.200 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2002 | 11 | 0.200 |
Why?
|
| Mitoxantrone | 1 | 2002 | 19 | 0.200 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 37 | 0.200 |
Why?
|
| Structure-Activity Relationship | 10 | 2014 | 80 | 0.200 |
Why?
|
| DNA Adducts | 5 | 2014 | 12 | 0.190 |
Why?
|
| Citric Acid Cycle | 1 | 2020 | 11 | 0.190 |
Why?
|
| Pyruvate Dehydrogenase Complex | 1 | 2020 | 18 | 0.180 |
Why?
|
| Urea | 3 | 2009 | 37 | 0.180 |
Why?
|
| DNA, Neoplasm | 3 | 2013 | 55 | 0.180 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2020 | 37 | 0.180 |
Why?
|
| Tissue Array Analysis | 1 | 2019 | 34 | 0.170 |
Why?
|
| Lung Neoplasms | 4 | 2014 | 409 | 0.170 |
Why?
|
| Myeloid Cells | 1 | 2019 | 39 | 0.160 |
Why?
|
| Adenine | 2 | 2010 | 16 | 0.160 |
Why?
|
| Cell Proliferation | 4 | 2015 | 599 | 0.150 |
Why?
|
| Glycerophosphates | 1 | 2017 | 4 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 3 | 2006 | 168 | 0.140 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 44 | 0.140 |
Why?
|
| Solubility | 3 | 2008 | 37 | 0.140 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 761 | 0.130 |
Why?
|
| Prodigiosin | 2 | 2006 | 2 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 85 | 0.120 |
Why?
|
| Cell Cycle | 1 | 2014 | 77 | 0.110 |
Why?
|
| Cisplatin | 3 | 2012 | 77 | 0.110 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 39 | 0.110 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2015 | 22 | 0.110 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 65 | 0.110 |
Why?
|
| Tamoxifen | 1 | 2013 | 56 | 0.110 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 104 | 0.110 |
Why?
|
| Fluorescent Dyes | 1 | 2013 | 48 | 0.110 |
Why?
|
| Carboxylic Acids | 1 | 2012 | 2 | 0.110 |
Why?
|
| Small Molecule Libraries | 1 | 2012 | 11 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2017 | 629 | 0.100 |
Why?
|
| Chelating Agents | 2 | 2009 | 17 | 0.100 |
Why?
|
| Animals | 7 | 2020 | 7466 | 0.100 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 4 | 2012 | 33 | 0.100 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 2012 | 94 | 0.090 |
Why?
|
| Cell Survival | 3 | 2020 | 286 | 0.090 |
Why?
|
| Alkylating Agents | 1 | 2010 | 5 | 0.090 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2009 | 6 | 0.090 |
Why?
|
| Organogold Compounds | 1 | 2009 | 4 | 0.090 |
Why?
|
| Antitubercular Agents | 1 | 2009 | 8 | 0.090 |
Why?
|
| Platinum Compounds | 1 | 2009 | 3 | 0.090 |
Why?
|
| 2,2'-Dipyridyl | 1 | 2009 | 3 | 0.090 |
Why?
|
| Cell Line | 2 | 2015 | 435 | 0.080 |
Why?
|
| Guanidine | 1 | 2008 | 3 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2007 | 565 | 0.080 |
Why?
|
| Carboplatin | 1 | 2007 | 48 | 0.070 |
Why?
|
| Alkaloids | 1 | 2006 | 9 | 0.070 |
Why?
|
| Dinoprostone | 1 | 2006 | 31 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2006 | 66 | 0.070 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 47 | 0.070 |
Why?
|
| Taxoids | 1 | 2006 | 59 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2020 | 687 | 0.070 |
Why?
|
| Deoxycytidine Kinase | 1 | 2005 | 2 | 0.060 |
Why?
|
| Phospholipids | 1 | 2005 | 28 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2020 | 290 | 0.060 |
Why?
|
| Enzyme Activation | 2 | 2020 | 135 | 0.060 |
Why?
|
| Monoterpenes | 1 | 2004 | 3 | 0.060 |
Why?
|
| Genes, Neoplasm | 1 | 2004 | 18 | 0.060 |
Why?
|
| Stereoisomerism | 3 | 2008 | 22 | 0.060 |
Why?
|
| Buffers | 1 | 2003 | 9 | 0.060 |
Why?
|
| Ribonucleotide Reductases | 1 | 2003 | 6 | 0.060 |
Why?
|
| Biological Availability | 2 | 2016 | 21 | 0.060 |
Why?
|
| Rhodium | 1 | 2002 | 1 | 0.050 |
Why?
|
| Organometallic Compounds | 1 | 2002 | 23 | 0.050 |
Why?
|
| Models, Molecular | 3 | 2008 | 193 | 0.050 |
Why?
|
| Female | 5 | 2020 | 19953 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2002 | 14 | 0.050 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 14 | 0.050 |
Why?
|
| Flavonoids | 1 | 2002 | 18 | 0.050 |
Why?
|
| Leukemia, Myeloid | 1 | 2002 | 24 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2002 | 43 | 0.050 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2002 | 36 | 0.050 |
Why?
|
| Pyridines | 1 | 2002 | 76 | 0.050 |
Why?
|
| Imidazoles | 1 | 2002 | 91 | 0.050 |
Why?
|
| Transfection | 1 | 2002 | 191 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2002 | 292 | 0.050 |
Why?
|
| Mice | 3 | 2014 | 2475 | 0.050 |
Why?
|
| Phosphoserine | 1 | 2020 | 8 | 0.050 |
Why?
|
| Catalytic Domain | 1 | 2020 | 65 | 0.050 |
Why?
|
| Water | 2 | 2012 | 56 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2020 | 55 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 168 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2020 | 230 | 0.040 |
Why?
|
| Tissue Fixation | 1 | 2019 | 10 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2019 | 10 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 221 | 0.040 |
Why?
|
| Formaldehyde | 1 | 2019 | 11 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 488 | 0.040 |
Why?
|
| Crystallography, X-Ray | 2 | 2009 | 90 | 0.040 |
Why?
|
| Philadelphia Chromosome | 1 | 2017 | 4 | 0.040 |
Why?
|
| Protein Kinase C | 1 | 2017 | 31 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2017 | 60 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 73 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2017 | 82 | 0.040 |
Why?
|
| Random Allocation | 1 | 2017 | 220 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 261 | 0.030 |
Why?
|
| Molecular Structure | 2 | 2008 | 59 | 0.030 |
Why?
|
| Photochemistry | 2 | 2006 | 7 | 0.030 |
Why?
|
| Quinazolines | 1 | 2015 | 38 | 0.030 |
Why?
|
| G-Quadruplexes | 1 | 2014 | 8 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2014 | 35 | 0.030 |
Why?
|
| Valproic Acid | 1 | 2014 | 14 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 766 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 101 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2014 | 186 | 0.030 |
Why?
|
| Hydrazines | 1 | 2013 | 4 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 154 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 103 | 0.030 |
Why?
|
| Esters | 1 | 2012 | 10 | 0.030 |
Why?
|
| Chromatography, Reverse-Phase | 1 | 2012 | 1 | 0.030 |
Why?
|
| Cell-Free System | 1 | 2012 | 15 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 311 | 0.020 |
Why?
|
| DNA Cleavage | 1 | 2010 | 4 | 0.020 |
Why?
|
| Netropsin | 1 | 2010 | 3 | 0.020 |
Why?
|
| Vero Cells | 1 | 2009 | 3 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2009 | 27 | 0.020 |
Why?
|
| Ligands | 1 | 2009 | 80 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2008 | 11 | 0.020 |
Why?
|
| Polydeoxyribonucleotides | 1 | 2008 | 1 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2008 | 34 | 0.020 |
Why?
|
| Circular Dichroism | 1 | 2008 | 30 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 2008 | 48 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2007 | 24 | 0.020 |
Why?
|
| Infusions, Parenteral | 1 | 2007 | 66 | 0.020 |
Why?
|
| Sulfur Compounds | 1 | 2006 | 7 | 0.020 |
Why?
|
| Base Sequence | 1 | 2007 | 251 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 356 | 0.020 |
Why?
|
| Hydrogen Bonding | 1 | 2006 | 22 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2006 | 268 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2007 | 456 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2004 | 10 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2004 | 23 | 0.010 |
Why?
|
| Genes, ras | 1 | 2004 | 25 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2004 | 31 | 0.010 |
Why?
|
| Caspases | 1 | 2004 | 38 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 2004 | 75 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 95 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 161 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2004 | 142 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2004 | 189 | 0.010 |
Why?
|
| Time Factors | 1 | 2008 | 2152 | 0.010 |
Why?
|
| Chemistry | 1 | 2002 | 2 | 0.010 |
Why?
|
| Chemical Phenomena | 1 | 2002 | 3 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2002 | 14 | 0.010 |
Why?
|
| Cattle | 1 | 2002 | 103 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2002 | 82 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2004 | 261 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2002 | 87 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2002 | 7 | 0.010 |
Why?
|
| Mutation | 1 | 2004 | 488 | 0.010 |
Why?
|
| Middle Aged | 1 | 2007 | 11868 | 0.010 |
Why?
|